Taken together, for the first time, we found that kirenol could exert anti-inflammatory and anti-fibrotic effects in diabetic kidney disease via blocking both TGF-β/Smads and NF-κB signal pathways, as depicted in Figure 8. Here, TGFB1 is linked to diabetic kidney disease.